Menu Search
Equities

Annexin Pharmaceuticals AB (publ)

Q91:FRA

Annexin Pharmaceuticals AB (publ)

Actions
  • Price (EUR)0.031
  • Today's Change0.001 / 4.73%
  • Shares traded--
  • 1 Year change-35.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-52.45m
  • Incorporated2014
  • Employees4.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.